Humana faces significant earnings headwinds due to CMS reforms, star rating downgrades, and potential Medicaid clawbacks.

Raymond (NSE:RYMD) James has upgraded Humana’s stock rating from Market Perform to Outperform, setting a new price target of $315, citing the company’s strong performance and favorable drug mix.

This was the stock's second consecutive day of losses.

Humana Inc. closed 43.21% below its 52-week high of $406.46, which the company reached on July 18th.

Humana (HUM) backs reforms on extra Medicare Advantage payments from home visits and chart review. Read more here.

On June 3, Bernstein SocGen Group analysts reiterated an ‘Outperform’ rating on Humana Inc. (NYSE: HUM) and a $313 price ...

Buying $100 In UHS: If an investor had bought $100 of UHS stock 20 years ago, it would be worth $607.28 today based on a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...